Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

APTO has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a research note on Friday, June 14th. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price target on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group reduced their price target on shares of Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average price target of $14.83.

Aptose Biosciences Trading Down 1.6 %

Shares of APTO stock opened at $0.75 on Friday. Aptose Biosciences has a 12 month low of $0.71 and a 12 month high of $5.10. The stock has a market cap of $13.53 million, a PE ratio of -0.12 and a beta of 1.27. The company’s fifty day moving average price is $1.04 and its 200-day moving average price is $1.59.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. On average, sell-side analysts forecast that Aptose Biosciences will post -2.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.